Semax: Mechanism, Evidence, and Dosing Protocols

Research disclaimer: Semax is sold for research purposes only and is not intended for human consumption. The information below is drawn from published scientific literature.

Evidence Tier

Human clinical use in Russia — registered medicine for stroke, TBI, and cognitive decline. Limited Western RCT data. Stronger human evidence base than most nootropic peptides.

Semax is not a grey-area research chemical in Russia. It is a registered pharmaceutical, prescribed and dispensed in pharmacies for neurological indications. That does not make it proven by Western regulatory standards, but it means it has been through a level of clinical evaluation far beyond what most peptides ever receive.

What Is Semax?

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1980s. It is a modified analog of the ACTH(4-7) fragment — a sequence from adrenocorticotropic hormone that has cognitive activity — with a Pro-Gly-Pro C-terminal extension that dramatically extends its biological half-life from minutes to hours.

The Pro-Gly-Pro extension does two things: it prevents rapid enzymatic degradation, and it is itself bioactive — this tripeptide is a fragment of collagen and has independent neuroprotective and anxiolytic properties.

Semax is administered intranasally. The nasal mucosa has direct vascular access and proximity to the olfactory bulb, allowing rapid CNS entry. This is not incidental — the intranasal route was deliberately chosen to bypass the blood-brain barrier and reduce systemic exposure.

Mechanism of Action

BDNF and NGF Upregulation (Primary)

The most consistently documented effect of Semax is upregulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF). In rodent studies, a single intranasal dose increases BDNF mRNA expression in the hippocampus, cortex, and basal forebrain within hours. BDNF is the primary driver of synaptic plasticity, long-term potentiation, and neuronal survival. This is the mechanism most relevant to cognitive enhancement and neuroprotection.

Dopaminergic Modulation

Semax increases dopamine turnover in the frontal cortex and striatum. This mechanism underlies the focus and motivation effects and is why Semax is used clinically for ADHD-adjacent presentations in Russian practice. It does not directly agonise dopamine receptors — the effect appears to be upstream, via BDNF-dependent dopaminergic neuron support.

Melanocortin Receptor Activity

As an ACTH(4-7) analog, Semax binds melanocortin receptors (MC4R primarily), which are expressed throughout the brain and are involved in attention, learning, and stress response. This is the ancestral mechanism — the original ACTH fragment was studied for cognitive effects before Semax was synthesised. The Pro-Gly-Pro extension does not bind melanocortin receptors; those effects are carried by the ACTH(4-7) core.

Anti-inflammatory and Neuroprotective Effects

Semax reduces inflammatory cytokine production in neural tissue (particularly IL-6 and TNF-α) and protects against excitotoxicity-induced neuronal death. This is relevant to its clinical use in stroke recovery, where neuroinflammation extends the zone of injury beyond the initial ischaemic core.

Serotonergic Effects

Lower-evidence mechanistic data suggests modulation of serotonin turnover, which may contribute to the mood effects and stress resilience that some clinical reports document. This is less well-characterised than the BDNF and dopaminergic mechanisms.

What the Evidence Actually Shows

Stroke and Cerebral Ischaemia

The strongest clinical evidence. Multiple Russian trials show that Semax administration in the acute phase of ischaemic stroke reduces infarct size, improves neurological outcomes, and accelerates functional recovery. The mechanism — BDNF upregulation and anti-inflammatory activity — is directly relevant to the biology of ischaemic injury. This is Semax’s primary approved indication.

Traumatic Brain Injury

Clinical use is documented, and animal models consistently show neuroprotection following TBI. The anti-inflammatory mechanism is particularly relevant here, as secondary neuroinflammation after TBI causes significant additional damage.

Cognitive Decline and Dementia

Russian clinical data documents use in early cognitive decline and vascular dementia. Effect sizes are modest in the published trials. BDNF upregulation is a rational mechanism — BDNF levels are consistently low in Alzheimer’s and vascular dementia patients.

Optic Nerve Conditions

One of the more specific approved indications. Semax has been used clinically for optic neuritis and ischaemic optic neuropathy. The optic nerve is CNS tissue and the BDNF/NGF upregulation is relevant to nerve preservation.

ADHD

Used in Russian clinical practice for attention disorders. Not formally approved for this indication but prescribed off-label. The dopaminergic mechanism provides a plausible basis.

Healthy Cognitive Enhancement

The weakest extrapolation. The clinical evidence is built on patient populations with pathological conditions. The assumption that BDNF upregulation meaningfully improves cognition in a healthy brain with normal BDNF levels is reasonable but unproven. Effect sizes in healthy subjects are expected to be smaller than in pathological states.

What Is Not Established

• Human pharmacokinetic data for intranasal bioavailability — assumed based on clinical effects, not measured
• Optimal dosing in healthy subjects — all clinical protocols come from pathological populations
• Long-term safety in chronic healthy use
• Direct comparison to other nootropic peptides in controlled trials
• Whether the 0.1% or 1% concentration produces meaningfully different outcomes per microgram

Dosing Protocols (Research Context)

Cycle: Clinical protocols typically run 10–14 days. Researcher cycles commonly run 14–21 days on, 7–14 days off. Continuous use data does not exist.

Timing: Morning administration is typical. Second dose, if used, should be no later than early afternoon to avoid disrupting sleep.

Dosing note: 1 drop of 0.1% solution delivers approximately 50 µg. 1 drop of 1% solution delivers approximately 500 µg. Confirm with your specific supplier’s dropper calibration.

Administration

Semax is supplied as a ready-to-use nasal solution — no reconstitution required. Tilt head back slightly, administer drops to each nostril, breathe in gently. Alternating nostrils per dose is standard practice.

Storage: Refrigerate at 2–8°C. Do not freeze. Stable for several months refrigerated. The active peptide degrades faster at room temperature — refrigerate on arrival and between uses.

Summary

Semax is the best-evidenced nootropic peptide in this review series. Two decades of Russian clinical use, regulatory approval, and published trial data for multiple neurological indications give it a foundation that research-only compounds cannot match. The primary mechanisms — BDNF/NGF upregulation and dopaminergic modulation — are well-characterised and directly relevant to cognitive function and neuroprotection. The gap between clinical populations and healthy researcher use remains an important caveat. Within those limits, Semax is the starting point for serious cognitive peptide research.

See also: Semax data page · Cognitive Stack: Semax + Selank · Neuroprotection Stack: Cerebrolysin + Semax